An Exploratory Study of Nivolumab With or Without Ipilimumab According to the Percentage of Tumoral CD8 Cells in Participants With Advanced Metastatic Cancer
Phase of Trial: Phase II
Latest Information Update: 31 May 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cancer
- Focus Pharmacodynamics; Therapeutic Use
- 28 Nov 2018 Status changed from not yet recruiting to recruiting.
- 18 Oct 2018 Planned initiation date changed from 14 Sep 2018 to 17 Oct 2018.
- 06 Sep 2018 New trial record